ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,604.50
-5.50 (-0.34%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -5.50 -0.34% 1,604.50 1,604.00 1,605.00 1,615.50 1,599.50 1,611.50 4,229,866 16:35:09
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 13.40 66.04B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,610p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,820.00p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £66.04 billion. Gsk has a price to earnings ratio (PE ratio) of 13.40.

Gsk Share Discussion Threads

Showing 32426 to 32449 of 33275 messages
Chat Pages: Latest  1307  1306  1305  1304  1303  1302  1301  1300  1299  1298  1297  1296  Older
DateSubjectAuthorDiscuss
26/7/2023
19:10
Profit up. Guidance raised. How does this equal women don't make good Captains? Can't get my breath.
Gender irrelevant. Well done the CEO and management team!

pcok
26/7/2023
18:12
I genuinely struggle to think of another company with such poor sentiment towards its stock :(
rikky72
26/7/2023
17:39
For those that might be interested....

GSK plc 2023 Q2 - Results - Earnings Call Presentation


GSK plc (GSK) Q2 2023 Earnings Call Transcript



Prefer Haleon myself.

Decent results from GSK though has to be said.

geckotheglorious
26/7/2023
15:19
GSK needs a pharmaceutical/clinical scientist at the helm.... ;0)
tradermichael
26/7/2023
15:13
Is there an ETF of companies with women CEOs that people can trade?
strandwolf
26/7/2023
15:05
Way too many women getting over promoted for diversity reasons.

Allison Rose of Natwest behaved disgracefully. She was the leak of false information.
"An error of judgement" she claimed.
Political bias and thought she'd get away with it more like.

Where's BBC Verify???

Not a sausage on the atrocious breach of privacy and personal freedoms compared to them being all over it(BBC) when it first came to light.

geckotheglorious
26/7/2023
14:45
Same cut as Dame Alison...One look at them shows how gormless a lot of these egos are.
They only need open their mouths.
Mediocre individuals promoted way beyond what they merit. More suitable for managerial roles on shop floors of the likes of Tesco or B@Q.

cumnor
26/7/2023
14:27
As I said before that the only way GSK will see any sunshine is to win all the Zantac court cases
abdullla
26/7/2023
14:17
Promoted way over her capabilities
spoole5
26/7/2023
13:08
Emma's results announcement and QA session nearly finished. She clearly (sic) hasn't improved her presentation skills - full of erms, ums and aahs as usual
tradermichael
26/7/2023
11:25
GSK made a net profit from continuing operations for the second quarter of GBP1.62 billion ($2.09 billion) compared with GBP706 million a year earlier.

Net debt increased by GBP 1 billion primarily due to the net acquisition
cost of Bellus Health for GBP1.4 billion, dividends paid to shareholders
of GBP1.1 billion, and GBP 0.3 billion free cash outflow.

tradermichael
26/7/2023
11:17
Anhar: Just compare net debt to cash profits (EBITDA) to get a sense of whether the company can afford its existing loans.
tradermichael
26/7/2023
11:14
It started the day in the red most likely it will end in red too
abdullla
26/7/2023
11:02
Added to my holding last week - surely longer term this will recover and prosper.
mister md
26/7/2023
10:34
"STUNNING" TM?

Reasonable I'd say but hardly exciting let alone stunning.

And look at net debt, it's huge and increasing so that leverage is monstrous. That adds to the risk of holding GSK. Despite dumping a whole load of debt on to HLN, GSK continues to suffer outrageously high and growing debt levels.

I continue to hold for income as I have for the last few centuries as I rarely sell any of my holdings, but it continues to be a poorish performer for me, even taking HLN into account which I've retained. Divi cut and abysmal capital gain after all this time.

I hold a widely diversfied income port so that inevitably some shares do better than others, that's to be expected and is the whole point of industry diversification, but my GSK/HLN holding is amongst the worst of the very long term ones. This may change in future, but that's the current position and it has been like that for some time.

anhar
26/7/2023
08:17
A conference call and webcast for investors and analysts of the quarterly
results will be hosted by Emma Walmsley, CEO, at 12 pm BST on 26 July
2023. Presentation materials will be published on www.gsk.com prior
to the webcast and a transcript of the webcast will be published subsequently.

tradermichael
26/7/2023
08:07
Yeah I thought so too but as with many on results day, the share price doesn't reflect the positive news.

Keep hanging in there I guess and hope for a push north of 1450 soon 👍🏻

tuftymatt
26/7/2023
08:05
STUNNING RESULTS

Strong performance and momentum drive upgraded guidance


Sales and earnings growth delivered by key growth drivers
-- Q2 2023 sales +4% and +11% ex COVID
-- Vaccines sales +18%, +15% ex COVID with Shingrix +20%
-- Specialty Medicines sales -7%, +12% ex COVID with HIV +12%
-- General Medicines sales +8% with Trelegy +30%
-- Strong sales growth of products launched since 2017 including in
Vaccines and HIV contributing to step change in performance
-- Total operating profit and Total continuing EPS >100% driven by strong
operating performance and favourable movements in contingent consideration
liabilities
-- Adjusted operating profit +11% and Adjusted EPS +16% reflects strong
sales ex COVID and higher royalty income offset by increased investment
in R&D and new product launches

tradermichael
24/7/2023
08:16
GSK said Monday that its HIV prevention treatment cabotegravir has been recommended for marketing authorization in the European Union.

The London-listed pharmaceutical giant said the positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use is based on results from the HPTN 083 and 084 Phase 2b and Phase 3 studies where the treatment--given as few as six times a year--showed greater efficacy than a daily oral pre-exposure prophylaxis option in reducing the risk of HIV.

Cabotegravir long-acting injectable and tablets for HIV prevention is currently approved for use in the U.S., Australia, South Africa, Zimbabwe, Malawi, Botswana and Brazil as Apretude.

The treatment's submission to other regulatory agencies is continuing, GSK said.

tradermichael
24/7/2023
08:16
Results are Wednesday 26 July 2023
tradermichael
24/7/2023
08:02
When is the result?
mhrangoon
20/7/2023
19:29
Very enlightening!
ianood
20/7/2023
16:16
Wotserface was on the beeb lunchtime news spouting about something or other, can't remember what. So probably the same clip will be on at 6 o'clock - a chance to see the boss in action. Can't even remember if she was pushing gsk or not.
pierre oreilly
19/7/2023
15:47
Always optimistic TM, can't fault you for that :)
rikky72
Chat Pages: Latest  1307  1306  1305  1304  1303  1302  1301  1300  1299  1298  1297  1296  Older

Your Recent History

Delayed Upgrade Clock